Treatment of acute XXXX with infliximab, a retrospective study from three Danish hospitals.

@entity1 @entity134 @entity31 @entity1851
BACKGROUND: In acute @entity134 -refractory @entity31 , rescue therapy with infliximab has become a therapeutic option in @entity1 facing colectomy. Data on efficacy and safety in this setting are sparse. METHODS: @entity1 with @entity31 and acute and severe @entity134 -refractory disease, who were given infliximab as rescue therapy, were identified by a review of @entity1 ' records and databases of infliximab-treated @entity1 . Data on @entity1 background, concomitant medication, endoscopic and laboratory results, clinical activity and adverse events were collected. RESULTS: Fifty-six @entity1 , all admitted because of high disease activity of short duration, and failing high-dose glucocorticoid treatment, received infliximab treatment and were followed up for a median of 538 days (range 2-1769). Colectomy was avoided in 61% of cases. No fatalities were observed. Concomitant medication at the end of follow-up indicated a low number of relapses in @entity1 without colectomies. CONCLUSIONS: Our results show a lasting benefit of infliximab rescue therapy in 61% of @entity1 with acute, @entity134 -refractory @entity31 , a low incidence of late colectomies, and low frequency of @entity134 use in @entity1 who avoided colectomy. High levels of @entity1851 on admittance and at the first infliximab infusion were associated with colectomy. Our study adds to the growing experience of infliximab treatment of @entity1 with acute, @entity134 -refractory @entity31 .
